EMA ADVISES ON GATHERING PATIENT FEEDBACK FOR ONCOLOGY MEDICINES
May 1st, 2016THE EUROPEAN Medicines Agency (EMA) has published new guidance on using patient-reported outcome (PRO) measures in oncology studies. It outlines principles of scientific best practice rather than prescribing particular approaches to selecting and using PROs and advises on how patient-reported outcome data should be integrated in oncology clinical trials. *http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/04/WC500205159.pdf
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.